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Abstract
Background: Human papillomavirus (HPV) vaccines based on major capsid protein L1 are licensed in over 100
countries to prevent HPV infections. The yeast-derived recombinant quadrivalent HPV L1 vaccine, GARDASIL(R), has
played an important role in reducing cancer and genital warts since its introduction in 2006. The L1 proteins self-
assemble into virus-like particles (VLPs).
Results: VLPs were subjected to post-purification disassembly and reassembly (D/R) treatment during
bioprocessing to improve VLP immunoreactivity and stability. The post-D/R HPV16 VLPs and their complex with
H16.V5 neutralizing antibody Fab fragments were visualized by cryo electron microscopy, showing VLPs densely
decorated with antibody. Along with structural improvements, post-D/R VLPs showed markedly higher antigenicity
to conformational and neutralizing monoclonal antibodies (mAbs) H16.V5, H16.E70 and H263.A2, whereas binding
to mAbs recognizing linear epitopes (H16.J4, H16.O7, and H16.H5) was greatly reduced.
Strikingly, post-D/R VLPs showed no detectable binding to H16.H5, indicating that the H16.H5 epitope is not
accessible in fully assembled VLPs. An atomic homology model of the entire
HPV16 VLP was generated based on previously determined high-resolution structures of bovine papillomavirus and
HPV16 L1 pentameric capsomeres.
Conclusions: D/R treatment of HPV16 L1 VLPs produces more homogeneous VLPs with more virion-like antibody
reactivity. These effects can be attributed to a combination of more complete and regular assembly of the VLPs,
better folding of L1, reduced non-specific disulfide-mediated aggregation and increased stability of the VLPs.
Markedly different antigenicity of HPV16 VLPs was observed upon D/R treatment with a panel of monoclonal
antibodies targeting neutralization sensitive epitopes. Multiple epitope-specific assays with a panel of mAbs with
different properties and epitopes are required to gain a better understanding of the immunochemical properties of
VLPs and to correlate the observed changes at the molecular level. Mapping of known antibody epitopes to the
homology model explains the changes in antibody reactivity upon D/R. In particular, the H16.H5 epitope is partially
occluded by intercapsomeric interactions involving the L1 C-terminal arm. The homology model allows a more
precise mapping of antibody epitopes. This work provides a better understanding of VLPs in current vaccines and
could guide the design of improved vaccines or therapeutics.
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The use of recombinant virus-like particles (VLP) as
immunogens or vaccines has proven increasingly suc-
cessful in recent years [1]. Most vaccines against viral
diseases have traditionally relied on attenuated virus
strains or inactivation of infectious virus. Self-assembly
of recombinant viral capsid proteins and corresponding
capsomeres into empty capsids is a promising strategy
for production and design of virus-like particles (VLPs)
for contemporary vaccines. The resulting VLPs may eli-
cit a protective immune response by mimicking the
authentic epitopes of virions. Recent VLP-based HPV
vaccines (quadrivalent GARDASIL
® from yeast and
bivalent Cervarix
® from insect cells) have been success-
ful in preventing HPV infection and- HPV-related can-
cer-associated genital warts [2-7]. HPV virions contain
3 6 0c o p i e so fL 1a n du pt o7 2c o p i e so fL 2 ,w h i c h
assemble into an icosahedral, T = 7 structure of 55-60
nm in diameter with one L2 molecule being at the cen-
tral opening of each capsomere [8]. L1 alone, when
expressed in insect or yeast cells, self-assembles into
VLPs. The VLP stability can be improved by oxidative
maturation [9,10] or reassembly [11,12]. The immuno-
genicity of purified VLPs that did not undergo a reas-
sembly step was confirmed through preclinical and early
clinical studies using HPV 16 L1-derived VLPs
expressed in yeast (Saccharomyces cerevisiae).
The spontaneous organization inside yeast cells of
pentameric L1 capsomeres into periodically packed
quasi-symmetric VLPs is controlled by thermodynamic
constraints via the combination of many intra- and
intercapsomeric forces. However, heterogeneity due to
assembly polymorphism is common for VLPs lacking
genetic material [13-15], in addition to a certain degree
of aggregation and formation of incomplete capsids dur-
ing expression in yeast cells and downstream bioproces-
sing. During the production of HPV16 L1 VLPs,
disassembly and reassembly (D/R) treatment was
employed during the bioprocessing to further improve
the VLP immunoreactivity, homogeneity and stability.
Disassembly was achieved with high pH, low salt and
presence of reducing agent to harness the presumed
intrinsic conformation switching mechanism of disas-
sembly into capsomeres during the viral entry and endo-
plasmic uncoating of the HPV virions [12,16]. Removal
of these disassembling agents under controlled condi-
tions enabled consistent particle reassembly from cap-
someres, yielding more homogeneous and fully
assembled VLPs. The characterization of the reas-
sembled HPV 16 VLPs was previously reported [12,16].
Here we quantify the impact of the D/R process on
epitope specific antigenicity of full-scale production lots
of HPV16 VLPs. Implementation of the D/R treatment
during bioprocessing was one of the crucial steps in
assuring the stability of VLPs, during pivotal clinical
trials and eventually in Gardasil
® (licensed for human
use in 2006). A panel of non-overlapping mAbs (Table
1), recognizing conformational as well as linear epitopes,
was utilized as orthogonal molecular probes for the sur-
face structural and functional assessment of the reas-
sembled HPV 16 VLPs. Using solution competitive
enzyme-linked immunosorbent assay (ELISA), the bind-
ing to the VLPs for three neutralizing Abs showed sev-
eral fold higher antibody binding in the clinically
relevant epitopes. In contrast, three non- or weakly-neu-
tralizing mAbs recognizing conserved linear epitopes,
showed a significant decrease in antibody binding to
reassembled VLPs. In addition, the particle morphology
and binding of the highly neutralizing H16.V5 Fab was
visualized directly by cryo electron microscopy. Based
on previously determined high-resolution structures of
bovine papillomavirus and HPV16 L1 pentameric cap-
someres, we generated an atomic homology model of
the entire HPV16 VLP. Mapping of known antibody epi-
topes to the homology model explains the changes in
antibody reactivity to the more virion-like fully closed
VLPs upon reassembly.
Results
Effects of reassembly on individual epitopes by solution
antigenicity analysis
Studies were initiated to better understand the impacts
of the D/R process on the presumed clinically relevant
epitopes-particularly those known to be neutralizing in
pseudovirion neutralization assay [17,18,27] and to be
immunodominant when analyzed by competition assay
using human sera of naturally infected individuals [26].
Epitope specific antigenicity is important in understand-
ing of the VLP structures, particularly the presence of
the neutralizing epitopes and resemblance to authentic
virions. The properties and characteristics of the six
mAbs used in a solution antigenicity assessment by a
competitive fluorescence ELISA method are listed in
Table 1. H16.V5 is the best-characterized mAb against
HPV 16 and has the highest neutralizing efficiency and
activity of all mAbs studied [27,31]. H16.V5 recognizes
an epitope which is made of two peptide stretches com-
ing from two different loops of the L1 molecule-the FG
loop (266-297) and secondarily the HI loop (339-365) of
the adjacent L1 in the pentamer [27,32]. H16.V5 is used
as the detection Ab in a sandwich ELISA for VLP lot
release and product stability [19,20]. In order to dissect
the impact on individual epitopes on the VLPs due to
D/R, a solution competitive ELISA was developed, using
o n em A ba tat i m e .T h ef o r m a tw a sb a s e do ne q u i l i -
brium dissociation constant determination [28,33]
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no need to transfer a premixed Ag-Ab solution to the
Ag coated plate (see Methods). Solution antigenicity was
determined with VLPs in solution (both test sample and
reference), binding to a fixed amount of mAb in solu-
tion, in competition to a pre- or post-D/R “reagent”
VLP sample immobilized passively on the surface of the
plate. Figure 1 illustrates the opposing effects on the
mAb binding behaviors of VLPs pre- and post-D/R
treatment for H16.V5, H16.E70, H236.A2 and H16.J4
with the inhibition profiles from the competitive ELISA.
Quantitation of the relative antigenicity was achieved by
comparing the IC50 values of test samples with that of a
reference lot. Specifically in Figure 1, a pair of pre- and
post-D/R VLP samples from the same production batch
were used for comparative analysis. Not surprisingly,
after breaking up some aggregates in the purified VLPs,
the conformational and neutralizing Ab binding was
increased by a factor of 2-3.5-fold, as reflected by a
decrease in IC50 values as a result of disassembly (Fig-
ure 1A-C). The impact of D/R on the solution antigeni-
city is indicated by the arrow in Figure 1, with left
movement indicating enhanced antibody binding in
solution for post-reassembly VLPs. This is the desirable
outcome of the D/R process for yielding VLPs with opti-
mized H16.V5 epitope quality and quantity due to the
immunodominant nature and high neutralizing effi-
ciency of H16.V5. The enhanced V5 binding is an indi-
cation of more virion-like VLPs as a result of D/R. In
contrast, the H16.J4 binding was reduced by ~5-fold
upon VLP reassembly (Figure 1D). The D/R process was
also highly efficient and consistent with a yield greater
than 75%.
Consistency of the D/R process
Interestingly, the D/R process, similar to viral uncoat-
ing and virion assembly inside the cell, could be per-
formed with recombinant L1 reliably with high yield
and consistency. Neutralizing epitopes on L1 VLPs
were improved as desired, whereas a decrease of bind-
ing was observed for mAbs targeting linear epitopes as
ar e s u l to fD / R .As e to fe p i t o pe-specific antigenicity
data from IC50 assays with four mAbs is presented in
Table 2. During the developmental stages of Gardasil
®,
five lots were manufactured during the clinical testing
stage with one lot (C1) being just the purified VLPs
(without D/R). High consistency was demonstrated for
the VLP D/R process at production scale when multi-
ple lots of post-D/R VLPs were analyzed. Figure 2
shows the epitope-specific antigenicity for each mAb
as defined by the five developmental lots in clinical
testing stage ("clinical experience”,a ss p e c i f i e di n
Table 2), and the actual process performance during
post licensure production for commercial lots or “man-
ufacturing experience”. Consistency was demonstrated
with respect to the D/R process in improving the clini-
cally relevant epitopes on VLPs during late develop-
ment phase and post licensure vaccine production. As
indicated from the range of the commercial lots, we
can conclude that a) the D/R process was successfully
implemented at full scale; b) the range for the com-
mercial lots is tighter than the lots for gaining “clinical
experience” (due to the one pre-D/R lot used in early
clinical trials); c) the multifaceted epitope-specific anti-
genicity assessment (Table 2 and Figure 2) is critical to
assure the product comparability during a production
scale-up or a process upgrade.
Table 1 Characteristics of the HPV 16 mAbs used in the epitope specific antigenicity analysis.
mAb (subclass) Neutralizing
activity
Type
specificity
Epitope [critical amino acids] (Refs) KD
(nM)
c
Application
d
Conformational
epitopes
H16.V5 (G2b) Strong (330)
b Yes FG loop, residues 266-297 (and HI loop, residues 339-365),
[282, 50] [17,18]
< 0.1 cLIA, IVRP, IC50
[19-22]
H16.E70 (G2b) Strong (1)
b Yes Similar to V5, [285, 288, 266, 282] [23,24] 0.15 IC50
H236.A2 Strong (11)
b Yes HI loop, residues 339-365 (and FG loop 266-297) < 0.1 IC50
Linear epitopes
e
H16.J4 (G2a) Weak No 261-280 [17,25] 2-5 IVRP, IC50 [19,20]
H16.O7 No No 174-185 ~2
H16.H5 (G2b) No No 174-185 [23]
H16.V5 was identified as the mAb with highest affinity and also with highest neutralization efficiency a
a Due to the immunodominant nature of this epitope in the sera of naturally infected individuals [26] and its high affinity to VLPs, V5 is the detection Ab for the
sandwich ELISA for product batch release and stability testing [19,20]. In addition, it is also the mAb for the clinical serological assay with V5 as the marker in the
competition RIA, ELISA or Luminex based assay for analyzing the sera from vaccines during clinical trials or post-licensure monitoring [21,22]
b Relative neutralization efficiency (value in parenthesis) for the mAb was normalized to E70 [27]
c The KD values are estimated with equilibrium based, indirect binding ELISA or SPR based methods with post-D/R VLPs [28,29]
d In support of Gardasil
® development and commercial manufacturing
e Most linear epitopes are not type specific. The linear epitopes, such as that of J4, were identified with immunoreactivity of synthetic peptides to the sera of
patients with HPV infection and cervical neoplasms [25,30]
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Page 3 of 13Quantitating the changes in different epitopes upon VLP
reassembly
The impact on the antigenicity of VLPs probed by dif-
ferent mAbs is shown in Figure 3. Significant improve-
ments in the IC50, ~2-3.5-fold, were observed for the
epitopes for the conformation sensitive and neutralizing
mAbs-H16.V5, H16.E70 and H263.A2. Conversely, the
binding of three mAbs with linear epitope was markedly
reduced (Figure 3).
It was particularly striking that the epitope for H5 was
no longer detectable upon D/R treatment (Figure 3). In
the direct Ag binding experiments, H5 showed signifi-
cant binding to pre-D/R VLPs, but not to post-D/R
VLPs. This was also confirmed with the solution compe-
tition ELISA or IC50 assays. There was no detectable
H5 binding to post-D/R VLPs even in the solution com-
petition format where the VLPs are allowed to freely
interact with detecting mAb (H5) with only unbound
H5 being detected by surface immobilized VLPs. The
reduction of antibody reactivity with these linear epi-
topes and even the disappearance of reactivity with H16.
H5 upon D/R is consistent with results from a recent
report in which three mAbs (H5 in particular) targeting
linear epitopes study were shown to have little or no
binding to pseudovirions (structurally more similar to
virions as compared to recombinant VLPs), and no
neutralization activity, even at high concentration, in a
pseudovirion neutralizing assay [27,34].
Changes in epitopes and antibody footprints by surface
Plasmon resonance (SPR)
To complement the IC50 ELISA analyses of antibody
reactivity against HPV VLPs, we directly measured the
antibody binding affinities for pre- and post-D/R VLPs
SPR (Figure 4) by analyzing one mAb at a time without
a need of a label or secondary detection reagents [35].
Binding signals are directly related to the mass depos-
ited to the sensor chip for a given VLP:IgG binding pair.
Consistent with the ELISA data, the SPR binding affi-
nities for H16.V5 and H16.E70 were enhanced upon D/
R, while the SPR binding affinities or their footprints for
H16.H5, H16.J4 and H16.O7 were significantly reduced
or abolished (in the case of H16.H5). A pair wise map-
ping study delineated the approximate footprint size and
relative overlaps of the four mAbs (Figure 4).
Visualization of VLPs and their binding to H16.V5 by
cryoEM
The structure and morphology of various types of HPV
VLPs before and after D/R have been compared directly
by negatively stained transmission EM and atomic force
microscopy (AFM) in previous studies [12,16,37]. To
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Figure 1 Competitive fluorescence ELISA curves for H16.V5 (A), H16.E70 (B), H263.A2 (C) (conformational epitope and neutralizing)
and H16.J4 (D) (linear epitope and weakly neutralizing) on a pair of pre- and post-D/R HPV 16 L1 VLP lots. Fitted curves and the IC50
values were obtained with GraFit (20). Open dots correspond to pre-D/R VLPs; closed dots correspond to post-D/R VLPs. The relative IC50 values
(normalized to a reference lot) for multiple full-scale lots are listed in Table 2.
Zhao et al. Virology Journal 2012, 9:52
http://www.virologyj.com/content/9/1/52
Page 4 of 13visualize the VLPs in a more native aqueous environ-
ment, we visualized post-D/R HPV VLPs by electron
cryomicroscopy (cryoEM). An image of the sample (Fig-
ure 5A) shows that in addition to particles with the
Table 2 Manufacturing consistency and epitope specific
antigenicity testing of multiple lots of HPV16 VLPs-pre-
and post-D/R treatment.
Lot No.
a Epitope specific antigenicity (Relative IC50)
H16.V5 H16.E70 H263.A2 H16.J4
pre-D/R
C1 0.54 0.30 0.53 6.73
C2(pre-) 0.51 0.31 0.51 5.51
C3(pre-) 0.48 0.27 0.46 5.24
Ave. (n = 3) 0.51 ± 0.03 0.29 ± 0.02 0.50 ± 0.03 5.83 ± 0.80
post-D/R
C2 1.17 1.33 1.11 0.43
C3 0.89 0.94 0.95 1.05
C4 0.97 0.83 1.00 0.94
C5
b 1.00 1.00 1.00 1.00
K1 1.01 1.08 0.88 0.91
K2 0.76 0.83 0.82 0.73
K3 0.93 0.95 0.92 0.70
K4 0.94 0.95 0.92 0.88
Ave. (n = 8) 0.96 ± 0.10 0.99 ± 0.07 0.95 ± 0.06 0.83 ± 0.10
Solution antigenicity was assessed with a panel of four anti-HPV 16 L1 mAbs
in a competitive FL-ELISA. Data from three lots of pre-D/R and eight lots of
post-D/R are presented. Each reported relative IC50 value is an averaged value
from three independent measurements on three different plates with a typical
RSD% of 12-15%
a Developmental lots during clinical testing stage ("C lots”) and commercial
lots ("K Lots”)-see also Figure 2. Once the reassembly process was developed,
only the post-D/R lots were tested clinically. Therefore, no clinical experience
was gained with C2-pre-D/R and C3-pre-D/R, and these two lots are excluded
from the analysis and plotting for “clinical experience” (Figure 2)
b This lot was used as the reference lot in the relative antigenicity assay (or
relative IC50). Lot C5 was used as the reference lot for all antigenicity testing
and it was tested on every plate along with other test lots
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Figure 2 Consistency in epitope specific antigenicity for clinical
stage developmental lots ("C” lots) and commercial lots ("K”
lots) as probed with a panel of mAbs. Four mAbs were
employed to track the solution antigenicity of the various lots (see
relative IC50 values in Table 2) to provide additional quantitative
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reactivities of different antibodies to HPV16 VLPs by ELISA. Bar
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Figure 4 Quantitative assessment of the impact of D/R on the
binding affinities of different antibodies, specifically captured
by chemically immobilized RAMFc [36], to HPV16 VLPs by SPR.
(A) Enhanced binding of neutralizing mAbs (V5, E70) and greatly
reduced binding of linear epitope targeting mAbs (J4, O7 and H5)
upon VLP reassembly. (B) Relative footprint changes of anti-HPV 16
L1 mAbs and their approximate degree of overlapping in pre- and
post-D/R samples-data obtained with pair-wise epitope mapping.
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Page 5 of 13expected 55 nm diameter a substantial fraction of the
particles have a smaller diameter of 40-44 nm and a few
particles with a 20-nm diameter are also visible. Closer
inspection of the particles (Figure 5B, C) shows that
despite variations in the size and local curvature of the
post-D/R VLPs, the particles are closed and fully
assembled. Images of the HPV VLPs mixed with H16.
V5 Fab show that all particles are densely decorated by
the antibody regardless of their size (Figure 5D-F). How-
ever, we cannot rule out that other antibodies may be
sensitive to structural differences between the 40- and
55-nm particles. When whole IgG of V5 was used,
aggregates of VLPs were observed.
A significant fraction of the particles in the cryoEM
images have a diameter and capsomere arrangement
that is consistent with the atomic force microscopy
(AFM) data (Figure 6A, B). Moreover, the ~55 nm dia-
meter and capsomere arrangement, as visualized by sin-
gle particle image (AFM and cryoEM) are consistent
with the atomic homology model of HPV16 VLP that
we generated here (Figure 6C). The atomic homology
model of the HPV16 VLP was constructed by superim-
posing the crystal structure of the HPV16 L1 pentamer
[38] onto the core pentamer in the asymmetric unit of
the high-resolution cryoEM structure of bovine papillo-
mavirus type [39]. A single HPV16 L1 chain of was then
superimposed on the sixth chain of the asymmetric unit
of the BPV1 structure. HPV16 residues 2-21, 82-95,
404-437 and 475-488 were modeled based on the homo-
logous BPV1 residues in the BPV1 cryoEM. The atomic
model of the full T = 7 HPV16 VLP (Figure 7C) was
generated by applying standard icosahedral symmetry
operators to the asymmetric unit (see Methods for addi-
tional details).
Epitope mapping based on the antibody binding
affinities to post-D/R VLPs using an atomic model of
HPV16
To understand why the epitopes of certain antibodies
become more exposed upon D/R treatment of VLPs
while other epitopes become less exposed, we generated
an atomic model of the entire HPV16 (T = 7)VLP (Fig-
u r e6 )b yf i t t i n gt h ec r y s t a ls t r u c t u r eo fH P V 1 6L 1[ 3 8 ]
onto the 3.6 Å resolution cryoEM map of bovine papil-
lomavirus type 1 (BPV1) [39]. The epitopes of the anti-
bodies studied here have been coarsely mapped by
measuring antibody reactivity against overlapping syn-
thetic linear peptides (see Table 1 for references). The
H16.H5 and H16.O7 epitopes were mapped in this man-
ner to residues 174-185, in the EF loop [23]. While H16.
H5 showed significant binding on the purified VLPs
from yeast, H16.H5 did not bind post-D/R VLPs, and
D/R treatment significantly reduces H16.O7 binding
(Figures 3, 4). Residues 184 and 185 are not solvent-
accessible in the pentameric L1 capsomere and are
therefore unlikely to be part of any antibody epitope
(Figure 7B). Residues 174, 176 and 179-183 are fully
exposed in the VLPs (Figure 8A, B), implying that these
residues are not sufficient for H16.H5 binding or for
optimal H16.O7 binding. Residues 175, 177 and 178 are
occluded by the C-terminal arm of an adjacent cap-
somere in the HPV16 VLP (Figure 8A, B) but not in
pentameric capsomeres (Figure 7B). Moreover, we note
that in our atomic model Ser173 forms a hydrogen
bond with His431 from the C-terminal arm of an adja-
cent capsomere (Figure 8B). This interaction results in
the occlusion of Ser173 upon VLP assembly. We there-
fore conclude that the occlusion of residues 173, 175,
177 and/or 178 upon completion of VLP assembly with
all capsomeres in place is responsible for the loss in
binding to H16.H5 and H16.O7, with the HPV16-speci-
fic Val178 playing a key role (see Discussion).
H16.J4 is a weakly neutralizing antibody originally
identified by the immunoreactivity of the sera from
HPV infected patients with cervical cancer [17,30]. Like
Figure 5 (A) CryoEM image of HPV 16 VLPs post-D/R treatment
shows a field of well-formed closed spherical particles.( B,C)
Larger scale images of individual VLP particles show that the
individual capsomeres are arranged with a high degree of order. (D)
CryoTEM image of post D/R HPV 16 VLPs mixed with H16.V5 Fab
shows a similar field of particles densely decorated with antibody
fragment. (E, F) Larger scale images of individual particles show that
the antibody attachment is independent of the diameter of the
individual particles. Scale bar is 200 nm.
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Page 6 of 13Figure 6 HPV16 VLP dimensions and morphology.( A) Atomic force microscopy image of a post-D/R HPV16 VLP, adapted from [16]. (B)
CryoEM image of a post-D/R HPV16 VLP. The scale bar is 50 nm long. (C) Atomic model of the T = 7 HPV16 VLP. The scale bar is 50 nm long.
The model was generated as described in the Methods.
Figure 7 Atomic model of HPV16 L1 in the context of the T = 7 VLP.( A) A single subunit of L1 in the standard orientation. Residues 261-
297 are in red and form part of the H16.V5, H16.E70, H263.A2 and H16.J4 epitopes. Residues 339-365 are in pink and form part of the H263.A2,
H16.V5 and H16.E70 epitopes. Residues 174-185 are in dark green and form the H16.H5 epitope. Residues 111-130 are in blue and form the H16.
I23 epitope. (B) A pentameric L1 capsomere with the same coloring scheme as in (A) and with the subunit in the foreground in approximately
the same orientation as in (A).( C) A view of the HPV16 VLP surface with the capsomere in yellow in the same orientation as in (B) and heparin
oligosaccharides as they bind to L1 capsomeres shown in red. The atomic model was generated as described in the Methods.
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Page 7 of 13H16.O7, H16.J4 bound significantly more weakly to fully
assembled post-D/R VLPs than to pre-D/R VLPs (Fig-
ures 3, 4). The H16.J4 epitope has been mapped to resi-
dues 261-280 [17,25], in the first part of the FG loop,
which partially overlaps with the epitopes of H16.V5,
H16.E70 and H263.A2. The epitope is located in a loop
on the crown of the L1 capsomere (Figure 7B) and is
conserved across several types. Most of the residues are
exposed on the viral surface in the HPV16 VLP atomic
model, with the exception of residues 261-264 and 275-
277. These residues form packing interactions that
anchor the loop onto the core of the capsomere. Glu269
is partially occluded by Arg365, with which it forms a
salt bridge. Additionally, accessibility of Glu269 is
restricted by a number of other neighboring side chains
including that of Gln424 from the C-terminal arm of an
adjacent capsomere (Figure 8C). We conclude that the
partial occlusion of Glu269 upon completion of VLP
assembly may be responsible for the decrease in binding
to H16.J4, and that the epitope may also include resi-
dues 265-274 and 278-280 (see Discussion).
In contrast to H16.H5, H16.O7 and H16.J4, antibo-
dies H16.V5, H16.E70 and H263.A2 are neutralizing
and their binding to VLPs was enhanced upon D/R
treatment (Figures 3, 4). The epitopes of these three
antibodies are contained within two surface loops on
the crown of the L1 capsomere, residues 266-297 in
the FG loop and residues 339-365 in the HI loop
(Table 1, Figures 7B, 8C). Of these, the only residue
that may be occluded upon completion of VLP assem-
bly is Glu269, as noted above. Since binding was
enhanced upon D/R, Glu269 is unlikely to play an
important role in binding to H16.V5, H16.E70 or
H263.A2. Residues 289-297, 339-345, 355, 360, 362
and 364-365 can also be excluded from the epitopes
because these residues are not solvent-exposed in the
HPV16 L1 pentameric capsomere (or in VLPs). Resi-
dues 286-288, 357 and 363 are also largely buried. We
conclude that residues 266-268, 270-285, 346-354, 356-
359, 362 and 363 form the core of the epitopes of H16.
V5, H16.E70 and H263.A2 on the apex of a capsomere
(Figures 7, 8C).
Figure 8 Fine mapping of antibody epitopes on the HPV16 capsid.( A) Same view as in Figure 7B, with the H16.H5 epitope (residues 173-
185) shown in red. Side chains in the C-terminal arms of neighboring capsomeres that partially occluding the H16.H5 epitope are shown as
colored spheres (not red). The conserved disulfide bond between Cys175 and Cys428 is highlighted with green spheres. The HPV16-specific
Val178 is shown in black. (B) Close-up of the H16.H5 epitope from the subunit in the foreground of (A) with the same coloring scheme as in (A).
(C) Same view as in (A), with the H16.V5, H16.E70, H263.A2 and H16.J4 epitopes highlighted: residues 261-265 (H16.J4 epitope only) are in dark
green, residues 266-280 (in all four antibody epitopes) are in red, residues 281-297 (not part of the H16.J4 epitope) are in magenta. Residues 339-
365 are in pink (not part of the H16.J4 epitope). Glu269 is shown in black. (D) Same view as in (A), with the H16.I23 epitope (residues 111-130) in
red.
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ing mAbs are consistent with the loss in binding when
(pre-D/R) baculovirus derived HPV16 L1VLP-coated
plates are compared to HPV16 L1 + L2 pseudovirion-
coated plates [27]. Another unique mAb, H16.I23,
recognizing residues 111-130 (in strand D and the DE
loop), exhibited the same behavior: total loss of binding
to pseudovirions. Within this epitope only residues 126-
128 and 130 are exposed in the HPV16 atomic model.
These residues are also exposed in unassembled cap-
someres, and none of the buried residues are occluded
by intercapsomeric interactions associated with virus
assembly (Figure 8D).
Discussion
Biophysical data from AFM, cryoEM, dynamic light
scattering and sedimentation experiments show a signifi-
cant improvement in the morphology, homogeneity and
thermal stability of the HPV16 VLPs upon D/R treat-
ment [12,37]. Antigenicity, which can be measured in
vitro, is an accurate and convenient metric for product
quality and stability, as a surrogate marker for in vivo
immunogenicity of the VLP. For quantitative antigeni-
city analysis, sandwich ELISA has high specificity and
sensitivity and can be developed for VLP characteriza-
tion and product release with the desired mAbs. How-
ever, for bioprocessing or stability studies of final
vaccine products, the interpretation of sandwich ELISA
data can be complicated as both the capture Ab and
detection Ab contribute to the final assay signals. There-
fore, to understand the impact of D/R on VLPs for dif-
ferent epitopes, a set of fluorescence-based competitive
ELISA assays with high specificity and sensitivity, allow-
ing VLPs to freely interact with a given mAb in solution,
was developed for probing epitope specific antigenicity
on VLPs [28,29]. The quantitative ELISAs with half-
maximal inhibitory concentration (IC50), by putting
mAbs one at a time in the assay, yielded quantitative
i n f o r m a t i o no nt h ei m p a c to fD/R treatment on indivi-
dual epitopes.
Among an array of immunochemical assays for HPV
VLP epitope characterizations, including competition
ELISAs (IC50), sandwich ELISA, equilibrium dissocia-
tion constant determination, relative antigenicity and
pair-wise epitope mapping, the epitope specific relative
I C 5 0 ,o rr I C 5 0 ,a s s a yi st h em o s ts e n s i t i v ea s s a yw i t h
straightforward data interpretation due to the use of a
single mAb in the assay. A ~3-fold enhancement in
IC50 was observed for H16.V5 after D/R treatment of
VLPs. In the relative antig e n i c i t ya s s a yb yS P R ,t h e
enhancement was ~2-fold. In addition, in a sandwich
ELISA in which VLPs were captured with H16.J4 and
detected with H16.V5, a moderate 30%-50% increase
w a so b s e r v e d[ 1 9 , 2 0 ] .T h i si sn o ts u r p r i s i n gg i v e nt h a t
these two mAbs showed opposing effects for binding to
the post D/R VLPs. The sandwich assay implies a more
dominant contribution from the detection H16.V5 since
an overall increase of antigen content was seen, and
conversely a smaller contribution by H16.J4 due to
poorer capture of post-D/R VLPs (Figure 3B). Efficient
D/R was shown to yield more fully assembled and pre-
sumably more virion-like VLPs with greatly reduced
binding to H16.J4 and H16.O7, while rendering H16.H5
binding completely undetectable. This is consistent with
a study by Culp et al. [27] in which pseudovirion bind-
ing was essentially undetectable for H16.H5, H16.J4,
H16.O7 and H16.I23 while binding of each of these
antibodies to L1-only VLPs derived from insect cells
was readily detectable. It is thus conceivable that the
epitopes for H16.H5 and H16.I23 were initially exposed
in the imperfectly assembled VLPs after purification
(from yeast or insect cells), and subsequently became
inaccessible or buried after the formation of virion-like
seamless VLPs after D/R during bioprocess or in the L1
+ L2 pseudovirions. Since the H16.I23 epitope is not
close to any intercapsomeric interfaces, the loss of H16.
I23 binding to post-D/R VLPs and pseudovirions may
be due to the rigidification of loops on the capsomere
surface that may accompany particle assembly thereby
restricting accessibility to the epitope. Our observations
also caution against interpreting data from the widely
used sandwich ELISA, particularly with respect to the
dis- and reassembly of VLPs, where opposing and con-
voluted effects could be seen on the capture Ab and
detection Ab.
The events that are likely to occur during D/R treat-
ment on purified VLPs are: (1) breakdown of non-speci-
fic aggregates including disulfide-bonded aggregates (an
overall reduction in particle size and increase in mono-
dispersity were observed by dynamic light scattering and
analytical ultracentrifugation); (2) unmasking of some
virion-like epitopes previously hidden due to non-cova-
lent or covalent association with other VLPs or cap-
someres through aggregation or non-native disulfide
bond formation; (3) promotion of complete assembly of
the closed icosahedral VLPs; (4) reduction of non-native
disulfide bonds and formation of native and thermody-
namically preferred intra- and intercapsomeric disulfide
bonds; (5) formation of native electrostatic and hydro-
phobic interactions upon correct capsomere assembly by
formation of intercapsomeric disulfides [40,41]. Making
VLPs with epitopes resembling those of authentic vir-
ions is essential in vaccine production. Understanding
and quantitating the epitopes with multiple non-overlap-
ping mAbs on the recombinant VLPs may provide
insights on the understanding of not only serotype spe-
cific protection for vaccine types, but cross protection of
non-vaccine types, by current vaccines [42].
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onto the HPV16 VLP atomic model shows that inter-
capsomere contacts in the VLP can explain the observed
changes in antibody reactivity upon D/R and allow more
precise and more consistent mapping of the antibody
epitopes. Within the H16.H5 epitope (residues 174-185),
residues 175, 177 and 178 are occluded by the C-term-
inal arm of an adjacent capsomere in the HPV16 VLP
but not in pentameric capsomeres, suggesting that the
observed reduction of H16.H5 and H16.O7 antibody
reactivity to VLPs upon D/R is due to the occlusion of
one or more of these residues. Cys175 forms an inter-
capsomeric disulfide with Cys428 in the C-terminal arm
of a neighboring capsomere [39,43]. When the VLPs are
fully assembled during D/R treatment, solvent access to
the EF loop bearing Cys175 is thus occluded. VLPs that
bind to H16.H5 antibody are therefore likely to have
incomplete intercapsomeric disulfide formation, to be
missing some capsomeres, or to be distorted such that
H16.H5 can still access the epitope. However, residues
175 and 177 are widely conserved across HPV strains.
Since the observed reduction of H16.H5 and H16.O7
binding to VLPs upon D/R is limited to HPV16, the
reduction in binding cannot be fully explained by the
occlusion of residues 175 and 177. Residue 178, which
is a valine only in HPV16, is the only unconserved resi-
due to be occluded upon VLP assembly. We therefore
propose that Val178 plays a key role in H16.H5 and
H16.O7 binding to misassembled (pre-D/R) VLPs or to
unassembled HPV16 L1 in GST-L1 fusion protein [44]
or in individual capsomeres, and that the occlusion of
Val178 upon correct VLP assembly is largely responsible
for the loss of reactivity against these antibodies. More-
over, we note that in our atomic model Ser173 forms a
hydrogen bond with His431 from the C-terminal arm of
an adjacent capsomere (Figure 8A, B). This interaction
results in the occlusion of Ser173 upon VLP assembly.
Since the Ser173-His431 pair is present only in HPV16,
Ser173 may also be part of the H16.H5 and H16.O7 epi-
topes, even though Ser173 lies just outside the pre-
viously identified linear epitope of H16.H5 and H16.O7.
The occlusion of Ser173 upon VLP assembly would pro-
vide an additional explanation for the reduction in anti-
body reactivity. We note that epitopes that are near
interacapsomeric interfaces, such as those of H16.H5
and H16.O7, are more likely to exhibit antigenic differ-
ences between the 40-nm and 55-nm particles since
structural differences between the two types of particles
are likely to be concentrated at the interfaces between
capsomeres. However, there is no evidence of any anti-
genic differences between the two types of particles.
In contrast to H16.H5, VLP binding to antibodies
H16.V5, H16.E70 and H263.A2 is enhanced upon D/R
treatment. The 3.6-Å resolution cryoEM structure of
BPV1 and our atomic model of HPV16 do not, however,
suggest that any epitopes become exposed upon virus
assembly [39]. We conclude that the enhanced binding
to post-D/R VLPs by H16.V5, H16.E70 and H263.A2 is
most likely due to the decrease in aggregation in post-
D/R samples, which was observed by dynamic light scat-
tering with much smaller polydispersity indices (unpub-
lished data) and by AFM and EM images [12,16]. We
note that the epitope of these three antibodies contains
an unpaired cysteine, Cys345, which is located within a
few Ångström of the outer surface of the capsomere.
Cys345 may be exposed to solvent in misfolded or
improperly assembled VLPs, which could cause VLP
aggregation through the formation of non-native
disulfides.
Conclusions
H P V 1 6L 1V L P si nG a r d a s i l
® have undergone D/R
treatment to produce more homogeneous VLPs with
improved neutralizing epitopes, structure and stability.
The effects on VLPs due to D/R treatment are evident
in improving particle uniformity and size distribution
from AFM and cryoEM images. Markedly different anti-
genicity of HPV16 VLPs was observed upon D/R treat-
ment with a panel of monoclonal antibodies targeting
neutralization sensitive epitopes. For VLP-based vaccine
design and production, generating the virion-like epi-
topes consistently, keeping them stable and knowing
how to analyze them accurately are of paramount
importance. These mAbs targeting different epitopes
function as the indicators for the consistency and cor-
rectness of VLP assembly. Significant binding to surface
or buried linear epitopes (such as H16.J4, H16.O7 and
H16.H5) is an indication of poor folding and/or incom-
plete assembly, as explained by the atomic model in this
report. A similar approach, using the immunoreactivity
of a mAb recognizing a linear epitope, was employed to
probe the “incorrectly” or poorly folded erythropoietin
[45,46]. Multiple epitope-specific assays with a panel of
mAbs with different properties and epitopes are
required to gain a better understanding of the immuno-
chemical properties of VLPs and to correlate the
observed changes at the molecular level. This type of
insight into the variations in the VLP surface structure
could facilitate the process development and finalization
of desirable VLP product attributes and the formulation
composition for further pre-clinical and clinical vaccine
development.
Methods
HPV 16 L1 VLPs
Full length HPV16 L1 protein was over expressed in
yeast. Purification of the VLPs, and the D/R process at
lab scale was previously described [12,40] and the full
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dures. The protein concentration was determined with a
BCA method.
Anti-HPV 16 L1 mouse mAbs (IgGs) and fab of H16.V5
Mouse mAbs [17,18,27] were produced in cell culture or
ascites using the cell lines provided by Prof. Christensen
(Pennsylvania State University). Standard Protein A
chromatography was used to purify IgGs. The concen-
tration was determined with UV absorbance at 280 nm.
Purity of the IgGs (> 95% pure) was determined with
size exclusion HPLC and the isotype was verified with
IsoStrip (Roche).
In order to prevent cross-linking of the VLPs during
cryoEM experiments (with both IgG and Fab), Fab anti-
body fragments were prepared from the H16.V5
(IgG2b). Reduction of disulfide bonds and specific clea-
vage at the hinge region were achieved by adding a solu-
tion of H16.V5 (1.0 mg/ml) in 20 mM L-cysteine
hydrochloride monohydrate to immobilized papain on
agarose beads (Pierce), followed by gentle mixing for
complete digestion over the course of two days at ambi-
ent temperature. Supernatant containing the Fab frag-
ments was purified via gentle mixing with immobilized
Protein A (Repligen) for one hour. Fab fragments in
solution were concentrated using a 10 kDa filter (Cen-
triprep YM-10, Millipore). The completeness of the
cleavage of IgG and purified Fab was assessed with a
size-exclusion HPLC. Concentrations of the H16.V5 Fab
fragments were determined before and after filtration by
UV absorbance measurements at 280 nm using an Agi-
lent 8453 UV-Visible spectrophotometer.
Assessment of epitope specific antigenicity by
competitive fluorescence ELISA
Competitive fluorescence ELISA (FL-ELISA) of HPV
VLPs was employed to assess the median inhibitory con-
centrations (IC50) of antigen in solution with half- maxi-
mal binding. Briefly, a fixed amount of HPV 16 VLPs on
plate and varying amount of HPV L1 VLPs in solution
were allowed to compete for the binding to a constant
concentration of anti-HPV 16 mAbs at 10 or 20 ng/mL.
This assay was used to quantitatively measure the solu-
tion antigenicity of HPV L1 VLPs against a given mAb.
Reagent VLPs were passively adsorbed to a high-binding
microtiter plate at a fixed concentration (e.g. 5 μg/mL
of L1 protein and 100 μL per well for plate coating, pre-
or post-D/R VLPs). 1.5-fold serial dilutions of a refer-
ence lot and the test samples were performed on the
VLP coated assay plate using a Beckmann Biomek
®
2000 or 3000 Laboratory Automation Workstation. A
constant amount of the anti-HPV 16 antibody was then
added to the solution HPV 16 VLP dilution series and
the plate was incubated for 60 min. After washing away
components in solution (free antibody, free VLPs, and
VLP-antibody complex in solution), the antibody bound
to the surface immobilized VLPs was quantitated with
an alkaline phosphatase-conjugated rabbit anti-mouse
IgG antibody. For detection, 4-methylumbelliferyl phos-
phate (4-MUP) was used as a substrate. The substrate
forms the fluorescent substance 4-methylumbelliferone
(4-MU) in the presence of the immobilized alkaline
phosphatases. This fluorescence intensity was measured
with a fluorescence plate reader after 60-70 min fluores-
cence development. Percentage of inhibition was calcu-
lated based on the wells without any antigen present in
solution as a control, obtained on the same plate.
Curve-fitting and IC50 calculation were performed with
GraFit [47].
Quantitative assessment of impact on different epitopes
upon VLP reassembly by surface Plasmon resonance
(SPR)
Epitope specific antigenicity assessments using SPR with
a panel of mAbs were carried out using similar proce-
dures as described [36]. Briefly, using a Biacore 3000
instrument, CM5 sensor chips were prepared by cova-
lently coupling rabbit-anti-mouse IgG Fcg antibodies
(RAMFcg) through the carboxylate groups in the dex-
tran matrix on the sensor chip and the amine groups on
the RAMFcg using a Biacore Coupling Kit. The immobi-
lized RAMFcg antibodies on the chip surface were used
to capture anti-HPV 16 L1 mAbs. HPV VLP samples
(10 μg/ml) were injected onto the chip surface with spe-
cific mAbs captured. The extent of VLP binding to the
anti-HPV 16 L1 mAb was measured as the mass
increase at the sensor chip. The RU ratio was tracked
for the VLP binding (RUVLP) to a given amount of cap-
tured IgG (RUIgG). Results (i.e., the ratios of RUVLP/
RUIgG) from the samples are compared to results from a
reference lot tested in adjacent cycles.
For pair-wise epitope mapping, VLP was first captured
by H16.J4 (chemically immobilized) onto the sensor
chip surface. Then the VLP surface was saturated with
mAb1 by injecting mAb1 in high concentration (200 μg/
mL), then the remaining VLP surface was probed by the
binding of mAb2 to compare the degree of overlapping
or the decrease in mAb2 binding to the mAb1-saturated
VLP surface as compared to mAb2 binding to the free
VLP. Then, in a separate assay cycle, the order of bind-
ing (mAb1:mAb2) was reversed, by saturating VLP with
mAb2 first, followed by binding of mAb1.
CryoEM of HPV 16 VLPs in hydrated form
Samples were preserved in a thin layer of vitrified ice
over C-Flat holey carbon films (Protochips, Inc.) sup-
ported on 400 mesh copper grids. Samples were not
diluted prior to vitrification. Electron microscopy was
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Co.) operating at 120 keV equipped with a Gatan 4 k ×
4 k digital camera. Images were acquired, using the
Leginon data collection software [48], at a nominal mag-
nification of 50,000x, corresponding to 0.226 nm/pixel
at the specimen, using a dose of ~16 e
-/Å
2, and a nom-
inal defocus of ~3 μm. The images of the V5-Fab with
VLP were obtained by mixing them at 1:1 ratio based
on protein concentration, prior to applying to the grid.
Atomic model of T = 7 icosahedral HPV16 VLPs
The atomic homology model of the HPV16 VLP was
constructed as follows. The crystal structure of the
HPV16 L1 pentamer bound to heparin oligosacchar-
ides (PDB code 3OAE) [38] was superimposed onto
the core pentamer in the asymmetric unit of the high-
resolution cryoEM structure of the bovine papilloma-
virus type 1 (BPV1) outer capsid (PDB code 3IYJ) [39].
A single L1 chain of HPV16 was then superimposed
on the sixth chain of the asymmetric unit of the BPV1
structure. HPV16 residues 2-21, 82-95, 404-437 and
475-488 were absent or incompatible with particle
assembly in the crystal structure. These residues were
therefore modeled based on the homologous BPV1
residues in the BPV1 cryoEM structure using COOT
[49]. The energy and geometry of the resulting atomic
model of the full length HPV16 L1 VLP asymmetric
unit were minimized with REFMAC [50]. The atomic
model of the full T = 7 HPV16 VLP was generated by
applying standard icosahedral symmetry operators to
the asymmetric unit.
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